SteadyMD
Combining SteadyMD’s platform with DocGo will result in more productive delivery of patient care.
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
SteadyMD announced a $25 million Series B raise in March 2021.
Also: SteadyMD lands $25M for telemedicine platform and Lifelink System closes Series A round.
The raise will help SteadyMD further develop its technology platform and online services.